<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8205641</PMID><DateCompleted><Year>1994</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-9686</ISSN><JournalIssue CitedMedium="Print"><Volume>72</Volume><Issue>2</Issue><PubDate><Year>1994</Year></PubDate></JournalIssue><Title>Bulletin of the World Health Organization</Title><ISOAbbreviation>Bull World Health Organ</ISOAbbreviation></Journal><ArticleTitle>Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>225</EndPage><MedlinePgn>221-5</MedlinePgn></Pagination><Abstract><AbstractText>The immunogenicity of trivalent oral poliovirus vaccine (TOPV), which is less effective in tropical than in temperate areas, may potentially be improved in several ways, including increasing the number of doses. Little information is available on TOPV when more than 6 doses are given. The situation in Cuba provides a unique opportunity to relate the seroprevalence of neutralizing antibodies to the dose of TOPV because Cuba has not reported culture-confirmed poliomyelitis since 1973 and TOPV is only administered in twice yearly 1-week mass immunization campaigns. Sera from 2000 children nationwide were studied for neutralizing antibody among children who received 0, 2, 4, 6 and 8 doses of TOPV. These doses were administered in the period 1989-91, when TOPV (from the USSR) was being used with 500,000, 200,000, and 300,000 median tissue-culture-infecting doses (TCID50) for types 1, 2 and 3, respectively--the 5:2:3 formulation. Seroprevalence of neutralizing antibody after two TOPV doses was 91.5% for type 1, 90.8% for type 2, and 45.9% for type 3. Seroprevalence of type-3 neutralizing antibody after 6 doses remained low (73.4%), but increased to 83.5% after 8 doses (P &lt; 0.05). Although 16.5% of the children remained unprotected for type-3 infection even after 8 doses, mass campaign immunization strategies were sufficient to eradicate the transmission of wild poliovirus in Cuba. Because the seroprevalence of type-1 neutralizing antibody was high (91.5%) after two campaign doses, additional studies using different formulations are needed to determine whether simultaneous improvement in the type-3 response to two campaign doses can be achieved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mas Lago</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine Pedro Kouri, Ministry of Health, Havana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramon Bravo</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Andrus</LastName><ForeName>J K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Comellas</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Galindo</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>de Quadros</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Bull World Health Organ</MedlineTA><NlmUniqueID>7507052</NlmUniqueID><ISSNLinking>0042-9686</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003462" MajorTopicYN="N" Type="Geographic">Cuba</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="PIP">095701</OtherID><OtherID Source="POP">00238557</OtherID><OtherAbstract Type="PIP" Language="eng"><AbstractText>During December 1991-January 1992 in Cuba, health workers took blood samples from a nationwide sample of 2000 children aged 0-3 who received 0, 2, 4, 6, and 8 doses of trivalent oral poliovirus vaccine (TOPV) to determine the seroprevalence of poliovirus neutralizing antibodies for types 1, 2, and 3. Specifically, researchers wanted to learn whether TOPV becomes more effective as the number of doses increases. Since 1973, Cuba has conducted two mass immunization campaigns each year in February and April. During 1970-91, Cuba used a USSR-produced poliovirus vaccine that had 500,000, 200,000, and 300,000 median tissue-culture-infecting doses for types 1, 2, and 3, respectively. Wild poliovirus has not been transmitted in Cuba since 1973 (as of August 1993), indicating that the mass immunization campaigns without routine vaccine delivery have eradicated poliomyelitis in Cuba. The seroprevalence of poliovirus neutralizing antibodies for type 1 increased significantly between 2 and 4 doses (91.5% vs. 96.5%; p = 0.05), thereafter the increases were small and insignificant. The seroprevalence of poliovirus neutralizing antibodies for type 2 increased significantly between 2 and 4 doses (90.8% vs. 97.2%), with small insignificant increases thereafter. Two doses of TOPV induced a response against poliovirus type 3 in only 45.9% of cases. At 4 doses and 8 doses, it did increase significantly from the previous dose (71.2% and 83.5%, respectively; p 0.05). Further studies using other vaccine formulations would allow persons involved in global eradication efforts to determine whether two campaign doses can improve the immunogenicity of the type 3 poliovirus while also improving that of the type 1 poliovirus.</AbstractText></OtherAbstract><KeywordList Owner="PIP"><Keyword MajorTopicYN="N">Age Factors</Keyword><Keyword MajorTopicYN="N">Americas</Keyword><Keyword MajorTopicYN="Y">Antibodies</Keyword><Keyword MajorTopicYN="N">Biology</Keyword><Keyword MajorTopicYN="N">Caribbean</Keyword><Keyword MajorTopicYN="Y">Child</Keyword><Keyword MajorTopicYN="Y">Comparative Studies</Keyword><Keyword MajorTopicYN="N">Cuba</Keyword><Keyword MajorTopicYN="N">Delivery Of Health Care</Keyword><Keyword MajorTopicYN="N">Demographic Factors</Keyword><Keyword MajorTopicYN="N">Developing Countries</Keyword><Keyword MajorTopicYN="N">Diseases</Keyword><Keyword MajorTopicYN="N">Health</Keyword><Keyword MajorTopicYN="N">Health Services</Keyword><Keyword MajorTopicYN="Y">Health Surveys</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="Y">Immunization</Keyword><Keyword MajorTopicYN="N">Immunologic Factors</Keyword><Keyword MajorTopicYN="N">Latin America</Keyword><Keyword MajorTopicYN="N">Measurement</Keyword><Keyword MajorTopicYN="N">North America</Keyword><Keyword MajorTopicYN="N">Physiology</Keyword><Keyword MajorTopicYN="Y">Poliomyelitis--prevention and control</Keyword><Keyword MajorTopicYN="Y">Poliomyelitis--transmission</Keyword><Keyword MajorTopicYN="N">Population</Keyword><Keyword MajorTopicYN="N">Population Characteristics</Keyword><Keyword MajorTopicYN="Y">Prevalence--changes</Keyword><Keyword MajorTopicYN="N">Primary Health Care</Keyword><Keyword MajorTopicYN="Y">Research Report</Keyword><Keyword MajorTopicYN="N">Studies</Keyword><Keyword MajorTopicYN="Y">Vaccines--administraction and dosage</Keyword><Keyword MajorTopicYN="N">Viral Diseases</Keyword><Keyword MajorTopicYN="N">Youth</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8205641</ArticleId><ArticleId IdType="pmc">PMC2486525</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S408-12</Citation><ArticleIdList><ArticleId IdType="pubmed">6740082</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hyg Epidemiol Microbiol Immunol. 1987;31(4):381-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2828465</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Public Health. 1992;13:239-52</Citation><ArticleIdList><ArticleId IdType="pubmed">1599587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Infect Dis. 1991 Sep-Oct;13(5):926-39</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 1991 Mar;10(3):222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2041671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>